GH & Secretagogues
Growth-hormone related peptides and secretagogues compared.
| CJC-1295 CJC-1295 DAC, Modified GRF 1-29 | Ipamorelin | Tesamorelin Egrifta | |
|---|---|---|---|
| Basic Information | |||
| Status | Research compound (not FDA approved) | Research compound (not FDA approved) | FDA approved (HIV-associated lipodystrophy) |
| Class | Growth hormone-releasing hormone analog | Growth hormone releasing peptide (GHRP) | Growth hormone-releasing hormone (GHRH) analog |
| Mechanism | Stimulates growth hormone release from the pituitary. Often combined with a GHRP for synergistic eff... | Stimulates ghrelin receptors to release growth hormone. Considered one of the mildest GHRPs with few... | Stimulates pituitary release of growth hormone, reducing visceral adipose tissue. |
| Dosing | |||
| Starting Dose | 100mcg 1-3x daily (no DAC) or 2mg weekly (with DAC) | 100-300mcg 2-3x daily | 2mg daily |
| Half-life | ~30 min (no DAC) or ~8 days (with DAC) | ~2 hours | 26-38 minutes |
| Administration | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection, once daily |
| Reported Outcomes (Grade) | |||
| Body Composition | D 23 | D 61 | D 68 |
| Sleep Quality | D 15 | D 42 | D 43 |
| Weight Loss | D 12 | D 25 | D 35 |
| Energy Levels | D 10 | D 14 | D 17 |
| Mental/Mood | D 8 | D 20 | D 19 |
| Appetite Suppression | D 5 | D 18 | D 22 |
| Blood Sugar Control | D 7 | D 15 | D 15 |
| Cardiovascular | — | D 6 | D 15 |
| Common Side Effects | |||
| Constipation | 14.8% | 8.8% | 7.4% |
| Nausea | 13.0% | 7.7% | 7.4% |
| Water Retention | 13.0% | 9.9% | 10.6% |
| Fatigue | 11.1% | 11.0% | 14.9% |
| Insomnia | 3.7% | 8.8% | 8.5% |
| Pricing | |||
| US Research Grade | $35.5 | $70 | $70 |
| China Research Grade | $9.25 | $6 | $17.85 |
| Research & Community | |||
| Research Articles | 2 | 1 | 28 |
| Community Posts | 78 | 253 | 365 |